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Previewsadditional signals integrated to produce
responses that are more tailored to the
insult? How does the hemidesmosome
pathway integrate and crosstalkwith other
STAT-mediated pathways? To which hu-
man diseases is this new signal-transduc-
tion mechanism relevant? And perhaps
most pressingly, how can we harness this
mechanism to enhance human health?
We might not know the answer to these
key questions yet, but with the new knowl-
edge described in Zhang et al., we are on
our way to finding out.208 Immunity 42, February 17, 2015 ª2015 EREFERENCES
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Fusobacterium nucleatummight be the cause or consequence of disease in many tissues in and outside the
mouth. In this issue of Immunity, Gur et al. (2015) suggest a new mechanism by which this oral commensal
might help cancer cells escape host immunity.The gastrointestinal tract accommodates
the vast majority of the microbes that
inhabit the human body. Fusobacterium
nucleatum, an anaerobic Gram-oral com-
mensal, is associated with periodontitis,
adverse pregnancy outcomes (APO), car-
diovascular disease (CVD), rheumatoid
arthritis (RA), inflammatory bowel disease
(IBD), and colorectal carcinoma (CRC)
(Han, 2015). How F. nucleatum might
contribute to the pathogenesis of such
diverse clinical spectrum is unknown.
One might ask whether the presence of
the bacterium in the amniotic fluid and
fetal membranes, for example, is a cause
or a consequence of pre-term labor and
stillbirth—the pathogenesis of which are
also largely unknown. F. nucleatum from
the maternal oral cavity has been re-
ported to translocate to fetal tissues and
cause stillbirth (Han et al., 2010).
F. nucleatum might cause periodontitis
and fetal demise in mice, by interacting
with NKp46 (Chaushu et al., 2012) orTLR4 (Liu et al., 2007) and triggering
inflammation.
One is however left wondering how
bacteria naturally resident in the oral
cavity find their way into the placenta,
let alone the amniotic sac (Figure 1).
Bacteria might access fetal tissues by
ascending from the uro-genital tract as a
consequence of cervical changes.Moving
from themouth to the colon seems amore
straightforward translocation for bacteria,
although F. nucleatum is usually not found
in stools—which reflect the composition
of the luminal flora—and is often found in
mucosal specimens of both healthy and
inflamed intestinal biopsies. This would
attest to the invasive nature of virulent
F. nucleatum subspecies. Invasive iso-
lates of F. nucleatum are indeed more
often associated with pathological intesti-
nal biopsies, including those from patients
with IDB or CRC. Oral bacteria might enter
the blood circulation during transient bac-
teremia and translocate to different sitesthrough this alternative route, whichmight
contribute to turning them into pathogens.
Is the bacterium a causative agent or is its
presence a consequence of the condition
or is it simply a passenger?
In this issue of Immunity, Gur et al. (2015)
suggest potential mechanisms that might
explain how F. nucleatum allies with can-
cer cells (Gur et al., 2015). The teammakes
a credible case that F. nucleatum inter-
feres with host immunity by engaging its
bacterial protein Fap2 with the inhibitory
immunoreceptor TIGIT on natural killer
(NK) and T cells (Figure 1). Immune cells
do infiltrate tumors in most patients and
in some patients the tumor micro-environ-
ment is inflammatory and conducive to a
productive response against cancer cells.
Particularly in CRC, the extent of lympho-
cytic infiltrate is a favorable prognostic
marker. Getting in the tumor and actually
destroying cancer cells are two separate
tasks and the latter is frankly a big ask of












Figure 1. An Oral Commensal Associates with Disease in and outside the Mouth
Fusobacterium nucleatum naturally resides in the oral cavity and is associated with periodontitis, a chronic
inflammatory condition, which in turn is associated with extra oral conditions, such as pre-term labor, rheu-
matoid arthritis, inflammatory bowel disease, and colorectal carcinoma. It remains unknown, however, how
oral commensal bacteria access extra oral sites, such as the placenta and the joints and how and what
turns them into pathogens. The Fap2 protein of the bacteria interacts with the inhibitory immunoreceptor
TIGIT on NK cells, thus inhibiting their cytotoxicity. This interaction might also occur in vivo, suppressing
tumor-infiltrating NK and T cells. In this way, F. nucleatum might contribute to progression of cancer.
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Previewsfactors conspire tomake the tumor escape
immune responses. Transforming growth
factor-b (TGF-b), for example, made by
tumor cells, T regulatory (Treg) cells and
myeloid-derived suppressor cells, are
one important immunosuppressive forces
in the tumor microenvironment. The
expression of ligands for inhibitory recep-
tors on T cells, including programmed
death-1 (PD-1), is of course one of the
decisive factors that sway the outcome of
lymphocytic infiltrates in favor of the pa-
tient or of the tumor. Indeed, inflammation,
immune destruction, and avoiding it are all
integral to the tumor microenvironment
and considered hallmarks of cancer.
Monoclonal antibodies that block inhibi-tory receptors revert T cell suppression,
and immune checkpoint blockers arguably
represent themost spectacular advance in
cancer immunotherapy.
Gur et al. found that F. nucleatum binds
to tumor cell lines and suppresses cyto-
toxicity mediated by primary human NK
cells. Using reporter cell lines, they then
showed that two laboratory strains of
F. nucleatum bind to TIGIT, which was
chosen as candidate among inhibitory
NK cell receptors because it is invariable
among individuals and expressed on all
NK cells—contrary to killer-cell immuno-
globulin-like receptors (KIR), which are
extremely variable and expressed only on
subsets ofNKcells. TIGIT binds ubiquitousImmunity 42,nectin and nectin-like cell adhesion mole-
cules CD155 and CD112, which can be
upregulated on cancer and infected cells
in response to DNA damage or Toll-like re-
ceptor (TLR) signaling, in that way acting
as danger and stress signals on diseased
cells (de Andrade et al., 2014). CD155
and CD112 engage not only TIGIT but
also co-stimulatory receptors on NK and
T cells, e.g., DNAM-1. DNAM-1 is a key
receptor for tumor immunosurveillance.
TIGIT, however, by binding the same li-
gands with higher affinity, outcompetes
DNAM-1 and suppresses immune re-
sponses, recapitulating a common theme
in immunology that is so well illustrated
by NK cell biology: Inhibitory receptors
prevail over activating receptors, unless
the system is perturbed with, for example,
immune checkpoint blockade. Targeting
TIGIT together with PD-1 indeed improves
response rates in mice with tumors (John-
ston et al., 2014). Gur et al. do test and
exclude the possibility that DNAM-1 inter-
acts with F. nucleatum. It remains to be
tested, however, whether a third, less
studied co-stimulatory receptor belonging
to the same family, CD96 interacts with
F. nucleatum. TIGIT was ectopically ex-
pressed on the NK cell line YTS, in which
it suppressed cytotoxicity of a lymphoma
cell line that has the TIGIT ligands.
F. nucleatum-mediated YTS inhibitory
was then shown to be dependent on the
immunoreceptor tyrosine-based inhibition
motifs (ITIMs) motifs in the intracellular
portion of TIGIT. However only one of
two clinical isolates of F. nucleatum from
human CRC samples bound to TIGIT and
inhibited YTS cells, while the other did
not. The two clinical isolates also differed
in their ability to cause hemagglutination,
the F. nucleatum binding TIGIT being
able to do so. Building upon this positive
correlation, the authors screened 1,000
laboratory mutants for hemagglutination
and 300 for YTS-TIGIT killing. The dual
screen resulted in two F. nucleatum labo-
ratory mutants that were both unable to
hemagglutinate and to inhibit cytotoxicity
of the YTS-TIGIT cell line. The transposon
used for the mutagenesis had disrupted
the sequence coding for Fap2, an adhesin
that interacts across species and which
was no longer expressed by the two
mutant bacteria. TIGIT was expressed on
the vast majority of tumor infiltrating lym-
phocytes (TIL) in CRC biopsies, including
on NK cells and CD4+ and CD8+ cytotoxicFebruary 17, 2015 ª2015 Elsevier Inc. 209
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PreviewsT cells (CTL). Due to the paucity of TIL ex-
tracted from CRC biopsies, functional
interrogation ex vivo was done on TIL
from melanoma biopsies and the authors
found that F. nucleatum inhibited both
CTL and CD4+ T cells. F. nucleatum in-
hibited also IFN-g production by memory
CD4+ T cells in the peripheral blood of
HCMV-infected donors.
In view of such powerfully and wide-
spread ability of some F. nucleatum strains
to inhibit lymphocytes (although the link
between TIGIT binding and hemagglu-
tination is unclear), it is surprising that
F. nucleatum activates NK cells in mice
in a model of periodontitis. The NK cell
receptor NKp46 directly recognized
F. nucleatum, triggeringNKcell production
of TNF-a (Chaushu et al., 2012), a power-
fully inflammatory cytokine that might
lead to bone destruction in the pathogen-
esis of periodontitis, which in turn is also
associated with APO, CVD, and RA. How
can one reconcile the proinflammatory
role of F. nucleatum in the periodontitis
model with the immunosuppression in hu-
man lymphocytes? Fap2 does not bind
mouse TIGIT, and therefore it might be
impossible to untangle in vivo the intri-
cacies of a potential me´nage a trois among210 Immunity 42, February 17, 2015 ª2015 EF. nucleatum, activating NKp46 and inhib-
itory TIGIT. It will also be important to test
whether and how F. nucleatum and other
commensals interact with innate lymphoid
cells (ILCs) other than NK cells, because
ILCs are clearly pivotal in regulating tissue
homeostasis and barrier immunity in res-
ponse to microenvironmental cues, in-
cluding microbes.
While we mull over the chicken and egg
question related towhether F. nucleatum is
the cause or consequence of the condi-
tions it is associated with, the work of
Gur et al. provide a new molecular path-
way that might help guide our thinking on
ways to address the important question
of how commensals turn into pathogens.
Despite the fantastic therapeutic advance
providedby immunecheckpoint blockade,
the response rate of cancer patients is still
far from ideal. With improved microbial
detection technology and due caution for
potential contamination (Salter et al.,
2014), cancer patients might be stratified
according to the presence of bacteria in
the tumor and, by targeting specific bacte-
ria or the inhibitory immunoreceptors they
interact with, one might add a weapon in
the oncologists’ arsenal. Dr. William Coley,
considered one of the founding fatherslsevier Inc.of cancer immunotherapy (reviewed in
Starnes C, 1992), might have found this
approach interesting or dismissed it as a
red herring.
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Mechanisms responsible for protective immunity against epicutaneous Candida infections are incompletely
characterized. In this issue of Immunity, Kashem et al. demonstrate that different Candida life forms engage
selected skin dendritic cell subsets in distinct compartments, resulting in qualitatively different immune
responses.Candida albicans is a ubiquitous com-
mensal fungus that colonizes human skin
and mucosal surfaces and also causes in-
fections. Mucocutaneous candidiasis is
a common condition that occurs both in
immune-competent and immunocom-
promised individuals. It has been estab-lished through genetic and immunological
studies that interleukin-17 (IL-17)-me-
diated immunity is critical for protec-
tion against mucocutaneous candidiasis
(Puel et al., 2010, 2011). Patients with
inactivating mutations in IL-17 and the
associated cytokine IL-6 develop a chronicand refractory form of candidiasis termed
chronic mucocutaneous candidiasis
(CMC) (Puel et al., 2011). Rare patients
with APECED (autoimmune poly-
endocrinopathy candidiasis ectodermal
dystrophy,alsoknownasautoimmunepol-
yendocrine syndrome) have neutralizing
